Skip to content
drillr.ai
Sign up

ALVO

Alvotech

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IS

$5.03
+0.60%
Ask drillr

  • Oct 14, 2026, 08:30 UTC

    Alvotech and Advanz Pharma Corp. Ltd. announced that AVT29 was submitted to the EUROPEAN MEDICINES AGENCY as a line extension to the existing marketing authorization for Mynzepli (aflibercept 2 mg).

    Source:

  • Oct 6, 2026, 20:30 UTC

    Alvotech and Lotte Biologics Co., Ltd. announced a long-term manufacturing partnership under which Lotte Biologics Co., Ltd. will produce drug substance for multiple Alvotech antibody biosimilar products at its Syracuse, New York facility for global supply.

    Source:

  • Oct 5, 2026, 08:00 UTC

    The FDA approved additional U.S. manufacturing capacity allowing Alvotech's SIMLANDI (AVT02) drug substance to be produced in either of its two Reykjavik drug substance suites.

    Source:

  • Sep 18, 2026, 09:43 UTC

    Fuji Pharma obtained manufacturing and marketing approval in Japan for two biosimilar products, ustekinumab BS 130mg intravenous infusion and golimumab BS 50mg subcutaneous autoinjector.

    Source:

  • Sep 16, 2026, 12:28 UTC

    Alvotech shares rose 5.58% to $5.30 in after-hours trading on September 16, 2026, ahead of an FDA review decision.

    Source:

  • Aug 21, 2026, 13:00 UTC

    Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for its proposed biosimilars AVT34 (durvalumab) and AVT87 (emicizumab) in the U.S. and selected Asian markets.

    Source:

  • Aug 19, 2026, 20:30 UTC

    Alvotech announced its financial results for the first half of 2026 and provided a business update on August 19, 2026.

    Source:

  • Jul 29, 2026, 13:25 UTC

    Alvotech announced that the FDA closed its inspection of its manufacturing facility in Reykjavik, Iceland, with a Voluntary Action Indicated classification.

    Source:

  • Jul 1, 2026, 08:00 UTC

    Alvotech secured a $75 million term loan facility by amending its existing credit agreement with GoldenTree Asset Management LP and other lenders.

    Source:

  • Jun 16, 2026, 03:50 UTC

    Alvotech priced a public offering of 22,666,667 ordinary shares at $3.75 per share, raising $152 million.

    Source:

  • Jun 8, 2026, 08:00 UTC

    Alvotech announced that the FDA accepted for review its Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio.

    Source:

  • Jun 5, 2026, 18:35 UTC

    Alvotech resubmitted Biologics License Applications (BLAs) to the FDA for its biosimilar candidates AVT05 and AVT06.

    Source: